This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Fecal Microbiota Transplantation in Patients With Ulcerative Colitis

This study is currently recruiting participants.
See Contacts and Locations
Verified December 2014 by Marko Kalliomäki, Turku University Hospital
Sponsor:
Information provided by (Responsible Party):
Marko Kalliomäki, Turku University Hospital
ClinicalTrials.gov Identifier:
NCT01961492
First received: October 9, 2013
Last updated: December 2, 2014
Last verified: December 2014
  Purpose
The purpose of this study is to find out whether a single fecal microbiota transplantation is an effective and safe treatment as an adjunct to standard therapy in patients with ulcerative colitis.

Condition Intervention Phase
Ulcerative Colitis Other: Fecal microbiota transplantation Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Single Fecal Microbiota Transplantation Via Colonoscope as an Adjunct Therapy in the Treatment of Ulcerative Colitis

Resource links provided by NLM:


Further study details as provided by Marko Kalliomäki, Turku University Hospital:

Primary Outcome Measures:
  • Activity of ulcerative colitis [ Time Frame: Within 1 year after the intervention ]
    Change from baseline in the Pediatric Ulcerative Colitis Activity Index (PUCAI) at 1 month, 3 months, 6 months, and 12 months.


Secondary Outcome Measures:
  • Colonic inflammation [ Time Frame: Within 1 year after the intervention ]
    Change from baseline in the fecal calprotectin at 1 month, 3 months, 6 months, and 12 months.

  • Colonic inflammation [ Time Frame: Within 1 year after the intervention ]
    Endoscopic Mayo score at 3 and 12 months after the intervention

  • Adverse events [ Time Frame: Within 1 year after the intervention ]

Estimated Enrollment: 40
Study Start Date: October 2013
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Fecal microbiota transplantation
A single fecal microbiota transplantation via colonoscope as an adjunct therapy to standard medical treatment
Other: Fecal microbiota transplantation
A single fecal microbiota transplantation through colonoscope
No Intervention: Standard medical treatment
Standard medical treatment as recommended by the ECCO Guidelines of UC therapy.

  Eligibility

Ages Eligible for Study:   1 Year to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • active ulcerative colitis (PUCAI 10-64) in whom fecal microbiota transplantation via colonoscope can be performed

Exclusion Criteria:

  • severe ulcerative colitis (PUCAI > 65)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01961492

Contacts
Contact: Marko Kalliomäki, MD marko.kalliomaki@utu.fi

Locations
Finland
Turku University Hospital Recruiting
Turku, Finland, 20520
Principal Investigator: Marko Kalliomäki, MD         
Sponsors and Collaborators
Turku University Hospital
Investigators
Principal Investigator: Marko Kalliomäki, MD Turku University Hospital
  More Information

Responsible Party: Marko Kalliomäki, Specialist, Turku University Hospital
ClinicalTrials.gov Identifier: NCT01961492     History of Changes
Other Study ID Numbers: 15881
Study First Received: October 9, 2013
Last Updated: December 2, 2014

Additional relevant MeSH terms:
Colitis
Ulcer
Colitis, Ulcerative
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases

ClinicalTrials.gov processed this record on September 19, 2017